<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570412</url>
  </required_header>
  <id_info>
    <org_study_id>Aldox Compassionate Use</org_study_id>
    <nct_id>NCT02570412</nct_id>
  </id_info>
  <brief_title>Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy</brief_title>
  <official_title>Compassionate Use of Aldoxorubicin in Sarcoma Patients Who Have Failed Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytRx</source>
  <brief_summary>
    <textblock>
      Compassionate use of aldoxorubicin in sarcoma patients who have failed prior chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a compassionate use protocol allowing sarcoma patients that have relapsed after prior&#xD;
      therapies and are not eligible for other protocols involving the evaluation of aldoxorubicin&#xD;
      to receive aldoxorubicin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aldoxorubicin</intervention_name>
    <description>aldoxorubicin administered at 350 mg/m2</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic or unrectable sarcoma that has either relapsed or was refractory to at leat&#xD;
             1 prior chemotherapy or immunotherapy regimen and for which no standard approved&#xD;
             therapy exists&#xD;
&#xD;
          -  Must not be eligible for another CytRx-sponsored clinical trial&#xD;
&#xD;
          -  Able to provide complete medical records for review by the CytRx Medical Monitor&#xD;
&#xD;
          -  Able to receive treatment at a site that is participating or has participated in&#xD;
             another CytRx-sponsored aldoxorubicin trial&#xD;
&#xD;
          -  Capable of providing informed consent and complying with trial procedures&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Measurable or evaluable tumor lesions according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Women must not be able to become pregnant (eg post-menopausal for at least 1 year,&#xD;
             surgically sterile, or practicing adequate birth control methods) for the duration of&#xD;
             the study&#xD;
&#xD;
          -  Women of child bearing potential must have a negative serum or urine pregnancy test at&#xD;
             the Screening Visit and be non-lactating&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy, palliative surgery and/or radiation treatment less than 30 days prior to&#xD;
             screening for non-target lesion&#xD;
&#xD;
          -  Exposure to any investigational agent within 30 days of screening&#xD;
&#xD;
          -  Central nervous system metastases that are symptomatic&#xD;
&#xD;
          -  Laboratory values: Screening serum creatinine &gt;1.5×ULN, ALT &gt;3×ULN, or &gt;5×ULN if liver&#xD;
             metastases are present, total bilirubin &gt;3×ULN, ANC &lt;1,500/mm3, platelet concentration&#xD;
             &lt;100,000/mm3, hematocrit level &lt;25% for females or &lt;27% for males, coagulation tests&#xD;
             (PT, PTT, INR) &gt;1.5×ULN&#xD;
&#xD;
          -  Anion gap &gt; 16 meq/L or arterial or venous blood pH &lt; 7.30.&#xD;
&#xD;
          -  Clinically evident congestive heart failure &gt; class II of the New York Heart&#xD;
             Association (NYHA) guidelines&#xD;
&#xD;
          -  Current serious, clinically significant cardiac arrhythmias, defined as the existence&#xD;
             of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V&#xD;
&#xD;
          -  Baseline QTc &gt;470 msec and/or previous history of QT prolongation while taking other&#xD;
             medications. Concomitant use of medications associated with a high incidence of QT&#xD;
             prolongation is not allowed&#xD;
&#xD;
          -  History or signs of active coronary artery disease with or without angina pectoris.&#xD;
&#xD;
          -  Serious myocardial dysfunction defined scintigraphically (eg MUGA, myocardial&#xD;
             scintigram) or ultrasound determined absolute LVEF &lt;45% of predicted&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Active, clinically signifiant serious infection requiring treatment with antibiotics,&#xD;
             anti-virals or anti-fungals&#xD;
&#xD;
          -  Major surgery within 3 weeks prior to enrollment&#xD;
&#xD;
          -  Substance abuse or any condition that might interfere with the subject's participation&#xD;
             in the study or in the evaluation of the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 6, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

